Serum concentration of adhesion molecules in postoperative biliary atresia patients: Relationship to disease activity and cirrhosis
Serum concentration of adhesion molecules in postoperative biliary atresia patients: Relationship to disease activity and cirrhosis
复制标题
DOI：
10.1053/jpsu.2001.25798
复制
发表时间：
2001-08-01
影响因子：
2.4
通讯作者：
Miyano, T
中科院分区：
文献类型：
--
作者：
Kobayashi, H;Horikoshi, K;Miyano, T
背景/目的：胆道闭锁（BA）与进行性肝纤维化有关，这可能是由涉及粘附分子的免疫异常介导的。本研究旨在探讨血清细胞间粘附分子-1（sICAM-1）、血管细胞粘附分子-1（sVCAM-1）与BA临床及病理严重程度的关系。方法：采用酶联免疫吸附法检测35例BA患者和20例健康对照者血清ICAM-1、VCAM-1水平。使用标准肝功能检查（LFT）和冷冻切片肝活检标本来确定肝脏状态。根据LFT结果，将BA患者分为I组（n = 10; LFT正常）、II组（n = 15; LFT升高，无黄疸）和III组（n = 10; LFT升高，黄疸）。组II中8例受试者，组III中所有受试者均患有门静脉高压症（PH）。Ⅲ组sICAM-1水平显著升高（1760.0 +/- 717.5 ng/mL），与组II（555.1 +/- 199.4 ng/mL）、组I（272.1 +/- 59.9 ng/mL）和对照组（256.3 +/- 71.6 ng/mL）相比。尽管第III组sVCAM-1水平显着升高（1932.9 +/- 282.6 ng/mL）与组II相比（1054.3 +/- 297.0 ng/mL），组I（605.4 +/- 112.4 ng/mL）和对照组（616.0 +/- 112.0 ng/mL; P <0.001），组I、组II或对照组之间无统计学显著差异。与没有PH的患者（827.3 +/- 151.7 ng/mL; P <0.01）相比，PH组II中BA受试者的sVCAM-1水平（1253.0 +/- 245.1 ng/mL）显著升高。PH对sICAM-1水平无影响。有较强的ICAM-1和VCAM-1的表达在增殖的胆管，内皮细胞，肝细胞在组III相比，组II和controls.Conclusions：在BA，sICAM-1和sVCAM-1水平可能是有用的终末期肝病的标志物，与sVCAM-1更具体的PH。ICAM-1和VCAM-1的诱导可能是一个重要的因素，在肝硬化的发展。小儿外科杂志36：1297-1301。Copyright（C）2001 by W.B.桑德斯公司
Background/Purpose: Biliary atresia (BA) is associated with progressive liver fibrosis, which may be mediated by immunologic abnormalities involving adhesion molecules. This study investigates the relationship between serum intercellular adhesion molecule-1 (sICAM-1), serum vascular cell adhesion molecule-1 (sVCAM-1), and the clinical and histologic severity of BA.Methods: Serum ICAM-1 and VCAM-1 levels were measured by enzyme-linked immunosorbent assay in 35 patients with BA and 20 healthy controls. Standard liver function tests (LFTs), and frozen section liver biopsy specimens were used to determine liver status. On the basis of LFT results, the BA patients were classified into group I (n = 10; normal LFTs), group II (n = 15; elevated LFTs, anicteric), and group III (n = 10; elevated LFTs, icteric). Eight subjects in group II, and all subjects in group III had portal hypertension (PH).Results: sICAM-1 levels were significantly elevated in group III (1760.0 +/- 717.5 ng/mL) compared with group II (555.1 +/- 199.4 ng/mL), group I (272.1 +/- 59.9 ng/mL) and controls (256.3 +/- 71.6 ng/mL). Although sVCAM-1 levels were significantly elevated in group III (1932.9 +/- 282.6 ng/mL) compared with group II (1054.3 +/- 297.0 ng/mL), group I (605.4 +/- 112.4 ng/mL), and controls (616.0 +/- 112.0 ng/mL; P < .001), there was no statistically significant difference between groups I, II, or controls. sVCAM-1 levels were elevated significantly in BA subjects in group II with PH (1253.0 +/- 245.1 ng/mL) compared with those who did not have PH (827.3 +/- 151.7 ng/mL; P < .01). PH did not affect sICAM-1 levels. There was strong expression of ICAM-1 and VCAM-1 in proliferating bile ductules, endothelial cells, and liver cells in group III compared with group II and controls.Conclusions: In BA, sICAM-1 and sVCAM-1 levels could be useful as markers of end-stage liver disease, with sVCAM-1 being more specific for PH. Induction of ICAM-1 and VCAM-1 may be an important factor in the development of cirrhosis. J Pediatr Surg 36:1297-1301. Copyright (C) 2001 by W.B. Saunders Company.